Ensartinib after lung cancer surgery for ALK-positive patients
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 3 trial tests whether ensartinib given after surgery can lower the risk of lung cancer coming back in people with ALK-positive non-small cell lung cancer. You may be eligible if your tumor was completely removed and your recovery and lab tests meet specific requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that was fully removed by surgery (no remaining cancer at the cut edges)
- Your cancer was ALK-positive on an official lab test (sent to the study’s central lab)
- Your cancer stage after surgery is Stage IB to Stage IIIB (T3N2M0)
- You have recovered from surgery and any standard post-op treatment, and you can start the study treatment
- Your daily functioning is good (ECOG 0 or 1) and you have enough blood counts and organ function on lab tests
- If you are able to get pregnant, you must have a negative pregnancy test at the start
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if anlotinib (a targeted therapy) can help prevent lung cancer from returning after surgery for patients whose tumors did not completely disappear after chemotherapy plus immunotherapy before surgery.
This trial tests whether taking ensartinib before surgery can help people with a specific type of lung cancer that has the ALK gene change. It is for those whose cancer is stage II or III and can be surgically removed.
This trial studies whether taking ensartinib (a targeted pill) after lung cancer surgery can lower the chance the cancer comes back. It is for people with ALK-positive non-small cell lung cancer (NSCLC) whose cancer has been fully removed and who have recovered from treatment.
This trial compares ensartinib with standard platinum-based chemotherapy as “adjuvant” treatment—medicine given after surgery to lower the chance the cancer comes back. It’s for people with stage IIA to IIIA ALK-positive non-small cell lung cancer who had their tumor surgically removed.
This trial tests different treatments after surgery for people with non-squamous lung cancer that has certain high-risk features. The goal is to find the best next step to lower the chance of the cancer coming back, based on the type of gene change in the tumor.
This trial tests the targeted therapy drug ensartinib given after surgery to prevent lung cancer from coming back. It is only for people whose tumor has an ALK gene change and who are in early to moderately advanced stages after complete removal.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.